Real-World Results from One Year of Therapy with Tivozanib
We report our one-year experience on the use of Tivozanib in metastatic Renal Cell Carcinoma (RCC) in n=23 patients treated within a year after approval. Tumor response according to RECIST criteria was PR in 39.1%, SD in 52.2% and PD in 8.7% of the patients. Median progression free survival (PFS) wa...
Salvato in:
| Autori principali: | , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
SAGE Publishing
2019-12-01
|
| Serie: | Kidney Cancer |
| Accesso online: | https://doi.org/10.3233/KCA-190073 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|